Login to Your Account



Onxeo's HCC drug bested by physician's choice in HCC trial

By Michael Fitzhugh
Staff Writer

Wednesday, September 13, 2017

Hopes that Onxeo SA's doxorubicin-loaded nanoparticle, Livatag, would finish a pivotal trial and be ready for filing as a new treatment for challenging cases of hepatocellular carcinoma were dashed as the drug failed to outperform standard-of-care therapies, such as oxaliplatin, gemcitabine or tyrosine kinase inhibitors. News of the results sent Onxeo shares (PARIS:ONXEO) down more than 50 percent and turned the company's attentions to finding a partner to advance Livatag, as it focuses on other programs in its pipeline.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription